Madrigal Pharmaceuticals, Inc. Share Price
Stocks
MDGL
US5588681057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 535.69 USD | -3.21% |
|
+0.95% | -7.95% |
| 14/07 | Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says | MT |
| 13/07 | Madrigal Pharmaceuticals Expands Rezdiffra Patent Protection With Three New Patents | MT |
| Market Cap | 1.28TCr 1.12TCr 1.03TCr 950.86Cr 1.79TCr 1,23100Cr 1.82TCr 12TCr 4.85TCr 60TCr 4.79TCr 4.69TCr 2,07400Cr | P/E 2026 * |
-77x | P/E 2027 * | 56.7x |
|---|---|---|---|---|---|
| Enterprise Value | 1.22TCr 1.07TCr 990.99Cr 911.43Cr 1.72TCr 1,18000Cr 1.75TCr 12TCr 4.65TCr 58TCr 4.59TCr 4.49TCr 1,98800Cr | EV / Sales 2026 * |
8.2x | EV / Sales 2027 * | 5.28x |
| Free-Float |
94.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Madrigal Pharmaceuticals, Inc.
| 1 day | -3.21% | ||
| 1 week | +0.95% | ||
| Current month | -0.17% | ||
| 1 month | +4.51% | ||
| 3 months | +1.69% | ||
| 6 months | +6.16% | ||
| Current year | -7.95% |
| 1 week | 522.7 |  | 560.08 |
| 1 month | 500.8 | | 569.44 |
| Current year | 416.21 | | 598.79 |
| 1 year | 286.44 | | 615 |
| 3 years | 119.76 | | 615 |
| 5 years | 52.33 | | 615 |
| 10 years | 6.6 | | 615 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Sibold
CEO | Chief Executive Officer | 59 | 08/09/2023 |
Mardi Dier
DFI | Director of Finance/CFO | 62 | 11/03/2024 |
David Soergel
CTO | Chief Tech/Sci/R&D Officer | 58 | 21/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Rebecca Taub
BRD | Director/Board Member | 74 | 01/07/2016 |
Richard Levy
BRD | Director/Board Member | 68 | 11/08/2016 |
James Daly
BRD | Director/Board Member | 64 | 27/06/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 17/06/26 | Baker Bros. Advisors LP
| Free | Company | 4,880 | 0.0212% | |
| 17/06/26 | Free | Director | 1,220 | 0.0053% | ||
| 17/06/26 | Free | Director | 1,220 | 0.0053% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.20% | +0.95% | +61.97% | +151.44% | 1.28TCr | |
| +0.21% | -0.79% | +56.02% | +57.39% | 5.38TCr | |
| +5.37% | +0.75% | +50.39% | +83.03% | 5.21TCr | |
| -0.08% | -0.62% | +5.53% | +409.46% | 2.35TCr | |
| +0.46% | +2.20% | -15.48% | -14.55% | 2.31TCr | |
| +3.46% | +0.79% | +34.01% | -4.47% | 1.94TCr | |
| -1.18% | -2.97% | +32.73% | -33.30% | 1.76TCr | |
| -1.67% | -8.56% | +163.95% | +284.69% | 1.52TCr | |
| +3.62% | -2.42% | +29.70% | +663.64% | 1.48TCr | |
| +0.02% | +0.36% | +27.07% | +183.04% | 1.41TCr | |
| Average | +0.82% | -1.88% | +44.59% | +178.04% | 2.46TCr | |
| Weighted average by Cap. | +1.45% | -2.06% | +43.64% | +140.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 149.17Cr 130.75Cr 120.86Cr 111.15Cr 209.72Cr 14TCr 213.09Cr 1.45TCr 566.48Cr 7.04TCr 560.13Cr 547.91Cr 24TCr | 220.96Cr 193.67Cr 179.02Cr 164.64Cr 310.65Cr 21TCr 315.64Cr 2.14TCr 839.1Cr 10TCr 829.69Cr 811.59Cr 36TCr |
| Net income | -21Cr -18Cr -17Cr -15Cr -29Cr -1.98TCr -29Cr -198.71Cr -78Cr -967.76Cr -77Cr -75Cr -3.33TCr | 31Cr 27Cr 25Cr 23Cr 43Cr 2.97TCr 44Cr 298.07Cr 116.84Cr 1.45TCr 115.53Cr 113.01Cr 5TCr |
| Net Debt | -53Cr -46Cr -43Cr -39Cr -74Cr -5.1TCr -76Cr -512.69Cr -200.97Cr -2.5TCr -198.72Cr -194.39Cr -8.6TCr | -109.47Cr -96Cr -89Cr -82Cr -153.91Cr -11TCr -156.38Cr -1.06TCr -415.72Cr -5.16TCr -411.05Cr -402.09Cr -18TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/26/21 | $535.69 | -3.21% | 2,21,101 |
| 17/26/17 | $553.48 | +1.46% | 5,28,309 |
| 16/26/16 | $545.53 | -0.86% | 2,38,337 |
| 15/26/15 | $550.25 | +2.49% | 2,64,309 |
| 14/26/14 | $536.86 | +1.10% | 2,41,715 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MDGL Stock
Select your edition
All financial news and data tailored to specific country editions
